FDA Approval
FDA Approves First Treatment for Ebola Virus
U.S. Food & Drug Administration
PR-M10-20-10Oct 15, 2020
Staff
Regeneron Adds 400 Jobs in Ireland
Regeneron
PR-M08-20-NI-46Aug 28, 2020
COVID-19
Regeneron Awarded a $450 Million Contract to Manufacture REGN-COV2
Regeneron
PR-M07-20-NI-008Jul 07, 2020
COVID-19 Clinical Trial
Sanofi and Regeneron Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial in Hospitalized COVID-19 Patients
Sanofi
PR-M04-20-NI-040Apr 28, 2020
Priority Review
FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola
Regeneron
PR-M04-20-NI-025Apr 17, 2020
Clinical Trials
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients With Severe, Inherited form of High Cholesterol
Regeneron
PR-M08-19-NI-049Aug 19, 2019
Marketing
Visual Marketing Strategy for Libtayo
Emilie Branch
Pharma's Almanac
PAO-M08-19-NI-005Aug 01, 2019
Bispecific Antibody
Regeneron’s Bispecific Antibody Candidate Shows Positive Results in Early Clinical Studies
Nigel Walker
Nice Insight
PAO-M12-18-NI-007Dec 05, 2018
Finance
Regeneron to Report Third Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2018
Regeneron
PR-M10-18-NI-027Oct 09, 2018
Study Results
Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Teva Pharmaceutical Industries
PR-M09-18-NI-051Sep 18, 2018
Clinical Data
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
Regeneron
PR-M05-18-NI-075May 21, 2018
Big Data
Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank
Regeneron
PR-M01-18-NI-020Jan 10, 2018
FDA Approval
Fresh RA Treatment from Sanofi/Regeneron Approved
Emilie Branch
Pharma's Almanac
PAO-M05-17-NI-024May 23, 2017